# Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, Division 3.2.1.1: Gene therapy medicinal product containing recombinant nucleic acid sequence(s) or genetically modified microorganism(s) or virus(es)

Extent: E+W+S+N.I.

The finished medicinal product shall consist of nucleic acid sequence(s) or genetically modified microorganism(s) or virus(es) formulated in their final immediate container for the intended medical use. The finished medicinal product may be combined with a medical device or active implantable medical device.
The active substance shall consist of nucleic acid sequence(s) or genetically modified microorganism(s) or virus(es).

---
Source: https://www.legislation.gov.uk/eudr/2001/83/annex/I/part/IV/division/3/division/3.2/division/3.2.1/division/3.2.1.1 (the official version)
Page: https://openlegislation.uk/eu-directive-2001-83/annex-I/part-IV/division-3/division-3.2/division-3.2.1/division-3.2.1.1
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.